healthcareBy Sydney Abbott, JD, Manager, Provider Economics and Public Policy, ACCC

After a recent hearing by the House Energy and Commerce Health Subcommittee, the Cancer Patient Protection Act of 2013 (HR 1416) is gaining support.  The bi-partisan bill was introduced by Congresswoman Renee Ellmers and now enjoys 97 co-sponsors.

Our fight is not over, however.  ACCC continues to educate other members of the House about the importance of this legislation.  ACCC recently met with Representative Erik Paulsen’s office, who is one of the latest members to sign onto HR 1416. We are continuing to work to identify a champion in the Senate.

HR 1416 would restore Medicare reimbursement for anti-cancer drugs and biologicals to pre-sequester levels.  Currently, the 2% sequester applies to everything billed to Medicare, including the reimbursement for anti-cancer drugs. Due to the high cost of cancer drugs, oncology is being disproportionally affected by the 2% across-the-board…

View original post 81 more words